Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01540526
Other study ID # CO10907
Secondary ID 2011-0575NCI-201
Status Completed
Phase Phase 1
First received
Last updated
Start date March 2012
Est. completion date December 2014

Study information

Verified date December 2014
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to learn more about the safety of an investigational drug, axitinib. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is available for research use only. Researchers will also see what changes happen to the tumors while taking the axitinib and after it is stopped (during the scheduled breaks), and what changes in the tumor may be responsible for this growth. This will be done by using a special kind of scan called an 18F-FLT PET/CT. This scan is considered an investigational type of scan and is not used for clinical care. These scans are not approved by the FDA, their use in this study is just for research purposes.

In addition, the investigators want to find out how the drug is processed and distributed in the human body. The investigators will also look at how different types of cancer are affected by axitinib.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date December 2014
Est. primary completion date September 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients must have histologically or cytologically confirmed solid malignancy (excluding lymphoma) that is metastatic or unresectable and for which no standard therapy exists.

- Patients must have measurable disease

- Must be >/= 18 years of age

- All patients need to be willing to undergo planned pharmacodynamic assessments, including serial PET imaging, plasma markers, and pharmacokinetic sampling.

Exclusion Criteria:

- Patients who have had chemotherapy, radiotherapy, experimental therapy or major surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered (to grade -Patients may not be receiving any other investigational agents.

- Patients with prior anti-VEGF directed therapy may be allowed only if approved by the PI and greater than 8 weeks since last exposure

- History of allergic reactions attributed to compounds of similar chemical or biologic composition to axitinib

- Patients with poorly controlled hypertension

- Patients who require use of therapeutic doses of coumarin-derivative anticoagulants

- Patients with any condition that impairs their ability to swallow and retain axitinib tablets are excluded.

- Patients with any of the following conditions are excluded: Serious or nonhealing wound, ulcer, or bone fracture; History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of treatment; Any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study entry; History of myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within 12 months prior to study entry; History of pulmonary embolism within the past 12 months; Class III or IV heart failure as defined by the NYHA functional classification system.

- Patients without appropriate lesion on CT scan for FLT-PET/CT imaging

- CYP3A4 inducers/inhibitors medications will be reviewed by the Principal Investigator.

- Steroid use is not recommended during axitinib treatment

- Patients with a pre-existing thyroid abnormality who are unable to maintain thyroid function in the normal range with medication are ineligible.

- Patients with known brain metastases should be excluded

- HIV-positive patients on combination antiretroviral therapy are ineligible

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
axitinib
7 mg PO BID days 1-14 in 21 day cycles.

Locations

Country Name City State
United States University of Wisconsin Carbone Cancer Center Madison Wisconsin

Sponsors (2)

Lead Sponsor Collaborator
University of Wisconsin, Madison Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacodynamic change on FLT-PET/CT baseline, cycle 1 weeks 2 and 3, pre-cycle 3, cycle 3 weeks 2 and 3
See also
  Status Clinical Trial Phase
Completed NCT01202370 - A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies Phase 1
Completed NCT00162136 - Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies. Phase 1
Recruiting NCT05006794 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Phase 1
Active, not recruiting NCT02537418 - Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens Phase 1
Completed NCT00033202 - This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor Phase 1
Recruiting NCT04492735 - The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
Completed NCT05866354 - To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies Phase 1
Completed NCT02640755 - Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase Phase 1
Terminated NCT00695370 - Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children Phase 2
Completed NCT02325739 - FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression Phase 1/Phase 2
Completed NCT00676299 - A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. Phase 1
Active, not recruiting NCT00090727 - Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma Phase 1
Terminated NCT01112397 - Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours Phase 1
Not yet recruiting NCT00751894 - Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5) Phase 2